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modify the presentation of schizophrenia (i.e. modiﬁer genes). The cor-
rect model may depend on the gene or variant in question and will re-
quire additional investigation.
The main innovation of this study lies in its connection of rare
sequence-derived variants to an impressive array of clinical features.
Like most trail-blazing studies, replication and use of larger samplesWhile we have now identiﬁed N100 common single nucleotide poly- compass all gene coding regions (known as the exome) and ultimatelymorphisms (SNPs) contributing to risk for the umbrella diagnosis of
schizophrenia (Schizophrenia Working Group of the Psychiatric
Genomics Consortium, 2014), the genetic contribution to variation in clin-
ical expression for schizophrenia is far less clear. Most prior work in this
area has focused on common variants (Bergen et al., 2009; Fanous and
Kendler, 2008), often in selected candidate genes, although, some recent
studies have used genome-wide association studies (GWAS) to investi-
gate symptom variation in schizophrenia (Docherty et al., 2015; Bergen
et al., 2014; Edwards et al., 2016; Fanous et al., 2012). The ﬁndings thus
far are inconclusive or unreplicated.
The role of rare genetic variants (b1% frequency) has been much
more challenging to study. Evidence is mounting for their involvement
in schizophrenia risk, but their rarity often necessitates aggregation
across genes or biological pathways for analyses (Purcell et al., 2014).
The study by Kranz et al. represents a much-needed step forward as
the ﬁrst to explicitly explore the role of rare genetic variation in expres-
sion of schizophrenia (Kranz et al., 2016).
For four genes (PTPRG, SLC39A13, TGM5, and ARMS/KIDINS220)
previously shown to have de novo or rare mutations in people with
schizophrenia, a sample of 48 ancestrally diverse familial and sporadic
schizophrenia cases were examined for novel or rare missense-coding
variants and their relationship to clinical characteristics (Kranz et al.,
2015a, 2015b). Fifteen of these patients carried at least one such variant.
The four or ﬁve individuals carrying altered forms of these genes in
functional domains were compared to non-carrier cases as well as con-
trols for a range of symptoms, IQ measures, memory task performance,
and other characteristics. For each gene, carriers exhibited somewhat
different features than non-carriers, suggesting two possible models:
1) they confer risk for forms of schizophrenia with distinct clinicalm.2016.03.008.
. This is an open access article underwill be essential to solidify these tenuous initial ﬁndings. For future
studies, the few genes studied so far will almost certainly grow to en-
involve the whole human genome. As the scope of these studies in-
creases, the scale will need to, as well. Since rare genetic variants are,
by deﬁnition, not observed often, the number of subjects that will be
needed for sufﬁcient statistical power to detect associations will be
even greater than the large samples currently used in GWAS.
Furthermore, while common genetic variants are often observed
across populations, rare variants aremore likely to be population specif-
ic. Therefore, combining subjects of different ancestry is an even greater
concern for studies of rare variants and their effects than formost genet-
ic studies. The diversity in ancestry represented in this study is a re-
freshing change from most genetic association studies, but potentially
clouds interpretation when the frequencies of the observed variants
are not precisely known across populations. False associations due to
“population stratiﬁcation” may occur. Furthermore, rare missense-
coding variants and novel missense-coding mutations are not compati-
ble with currently used GWAS methods, since only genetic polymor-
phisms a) above 1% minor allele frequency are analyzed and b) most
lie in the non-coding regions of the human genome.
Another difﬁculty facing this and other studies is the lack of annota-
tion detailing the effects of genetic polymorphisms and novel mutations.
Many times, changes of one single base to another have no inﬂuence at all,
while other times this could reduce (or increase) gene expression, change
or inactivate a protein, or even have lethal effects. Predictions of the ef-
fects are predominantly carried out “in silico” through computational al-
gorithms (e.g. PolyPhen2 and SIFT) with relatively little substantiation
from laboratory experimentation. Consequently, we have only a rough
idea of the true biological effects ofmost genetic variation in humans. Im-
provements in annotation will concomitantly enhance the interpretation
of studies connecting genetic variants and clinical features.
As noted by the authors, identifying gene-phenotype relationships
within psychosis will facilitate precision medicine efforts. Patients may
respond well to one medication but not another, and clinicians currently
have little to guide their decisions besides trial and error. The differentthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to different pharmacological manipulations, and understanding these
connections is critical to improving care for the affected patients. Howev-
er, muchmore research needs to occur before translation of these provi-
sional ﬁndings into clinical practice can occur.
The study by Kranz et al. (2016)) is an exciting peek into the future of
psychiatric genetics aswework towards amore ﬁne grained understand-
ing of the ways in which genetic variation contributes to the immense
variability in expression of psychotic illnesses. Investigations of relation-
ships between genetic variants and clinical features will shed light on
the etiology of schizophrenia in ways that will facilitate studies of the dif-
ferent biological mechanisms leading to this diagnosis and ultimately
generate targeted therapeutics for the different schizophrenia subtypes.
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